And there was I hoping that you were going to admit to being Phil Collins :)
Best Wishes
Paper Tiger
Disc: It IS Friday
Printable View
I can neither confirm nor deny. By the way:
From 1994 to 2010, Genesis operated as a biotechnology company based in Auckland, New Zealand, developing therapeutics for the treatment of cancer and diseases of the immune system and agricultural biotech projects.
Genesis established Solirna Biosciences Ltd to develop a novel single stranded gene silencing technology which acts through the RNAi mechanism.
In 2010 Genesis and Solirna ceased operations due to lack of funding.
I'll be keeping an eye on this one, would be great to see our potential market grow from West to Mid-west. Bring on the KP Deal.
http://www.modernhealthcare.com/arti...NEWS/311049997
http://www.henryford.com/body.cfm?id=37460
It was never my intent to advise anyone on what they should or should not do with their dosh, Schrodinger. Sorry if you got that impression. I am merely a participant in a long running and ongoing battle to understand the ins and outs of this company via a medium of Sharetrader along with other sources. I have retained a reasonable holding and await the results in November HY Interim. Especially of interest will be revenue and Trade receivables.
The recent newsletter indicated a lab throughput of around 19% over FY 2015. This could be a bit misleading if anyone considers that to be an indication of growth in revenue or lack of it.
But I suppose you have that all sussed anyway.
Cheers
Miner
Forsyth Barr Downgrades Expectations
http://www.odt.co.nz/news/business/3...fic-edge-views
From that ODT article;
"He said PEB had attributed the slowing growth to a seasonal downturn in the US"
I wasn't aware bladder cancer was seasonal or affected by economic downturns. Interesting.
''To gain access to the VA and reach these patients, we need to be approved and added to the Federal Supply Schedule ... we are now in the final stages of review,''
That does sound like good news. However, how long will the 'final stages' drag on for and what's to say the review won't decline them anyway. Guess this is where their favourite 'cusp of success' statement comes from.
Not even being able to find enough patients to run the KP trial - that's pretty concerning!
Nbt - reason being seasonality my friendQuote:
Originally Posted by nextbigthing;
The growth in throughput has fallen from 140% in the previous HY to only 19%. I can't make it any clearer than that for those that still think this thing has legs.
Good luck. Strongly recommend that people consider exiting or placing stops before the HY results are announced. They are going to be crap (IMHO).
KP trial---the good news is that they obviously have'nt gotten the 2000 patients yet for the trial (how many-who knows) so we cant deduct the at least 2000 (free)from the tests(if they only do 1 per patient)-(which could mean more paid tests)but does anyone really expect them to amount to much?--Bad news is that this looks to be dragging on longer and longer with KP trials.(who thought they would come up with 2000 patients so quickly in the first place?
The odds of decent sales are looking pretty slim by the sound of that report so I think its going to have to be faith alone as before unless there is a surprise.
That new (and expensive)drug for melanoma looks the real deal(featured on Sunday last night) How does that affect PEBs Melanoma patent?
Getting the bodies immune system to identify and fight cancer itself seems to be the way to go (exciting)
If PEB could somehow use its process of identifying bladder cancer to tipping off the immune system--that would be something to celebrate.
Biggest danger --as all this time passes-others are catching up
I think that was more Macs domain(although you certainly held him in high regard) I reckon 50% of my posts were in response to some of his assumptions. Is he permanently banned?
I just hope not to many took his word as gospel as it had potential to do real damage.
I think most are far more realistic now. It just shows the dangers of being ''married''to a company.
The ability to change ones mind ,even a little, is an asset.